BAI Announces 2020 Global Innovation Award Finalists
28.1.2021 16:30:00 EET | Business Wire | Press release
BAI announced the finalists for the 2020 BAI Global Innovation Awards, the industry’s prestigious awards program that celebrates new and innovative solutions in the financial services industry worldwide.
Now in its tenth year, the BAI Global Innovation Awards recognizes leading financial services organizations on a global scale. This year, the awards drew hundreds of nominations from industry leaders demonstrating how their organizations used innovation to tackle their challenges in creative, impactful ways. Each nomination is evaluated by the Innovation Circle, a panel of global financial services innovation leaders who weigh each submission on originality and impact on consumers, employees, communities and the industry to determine the top innovations of the year.
The 2020 BAI Global Innovation Awards finalists are:
Consumer Products of Services Innovation
- Bank Pekao S.A., Poland: PeoPay KIDS
- CaixaBank S.A., Spain: HolaBank – Onboarding + mortgageNow
- FNB Life, South Africa: Dynamic Life – Home
- Meridian Credit Union, Canada: Meridian’s Price Drop
- OneConnect Smart Technology Co., Ltd. (Shenzhen), China: Smart Fast Claim
Customer Experience Innovation
- Bank of Montreal, Canada: BMO AI Cashflow Prediction
- Commonwealth Bank of Australia: Bill Sense
- DBS Bank Ltd, Singapore: DBS Chatbot – Guided Conversation
- Finicity, United States: Empowering the Customer Through Open Banking & Credit Decisioning
- FNB Life, South Africa: We’ve Got You COVI(R)D
Human Capital Innovation
- Citizens Financial Group, United States: Jamie Virtual Career Assistant
- SberBank, Russia: Employee Digital Care Program
- Ziraat Bank, Turkey: Hidden Power of Communication
Internal Process Innovation
- CaixaBank S.A., Spain: The New Mobility Section at Now
- DenizBank, Turkey: Digital Scorecard
- ICICI Bank, India: OPTIMUS – Payment Invoicing and ID Card Issuance System
- OneConnect Smart Technology Co., Ltd. (ShenZhen), China: Smart Contract Cloud Platform
- SberBank, Russia: Contact Center Internal Improvement Process
Marketing Innovation
- Emirates NBD Bank, United Arab Emirates: Emirates NBD Anti-Phishing "It Wasn't Me" Campaign
- imaginTech S.A., Spain: New imagin, a New Way to Communicate
- Synchrony, United States: Millie: A Multi-Channel Personal Finance Platform for Women
RegTech Innovation
- Abu Dhabi Global Market Financial Center (ADGM), United Arab Emirates: ADGM and ClauseMatch collaborate to launch Regulation 2.0
- Fino Payments Bank, India: Enterprise Risk & Fraud Management solution
- KAL ATM Software, Germany: New approach to costly and disruptive ATM hardware upgrades
- Ping An Technology (Shenzhen) Co., Ltd., China: Pingan Beehive Federated Intelligence Platform
Small Business Products or Services Innovation
- Aliasware, Inc., United States: PayVus Small Business Credit Card
- Banco Bradesco, Brazil: Open Banking Initiative: Portal MEI, Solutions for the Individual Micro Entrepreneur
- İşbank, Turkey: TekCap
- RBC Ventures, Canada: Ownr
Societal and Community Impact Innovation
- Citi Ventures Studio, United States: City Builder
- Union Bank of the Philippines: UBX SeekCap
- Woodforest National Bank, United States: Woodforest CEI-Boulos Opportunity Fund
Congratulations to all the finalists of the 2020 BAI Global Innovation Awards. The winners will be announced in February. To learn more please visit BAI Global Innovation Awards.
About BAI
As a nonprofit, independent organization, BAI has delivered the financial services industry’s most actionable insights for more than 95 years, enabling leaders to make smart business decisions every day. We provide in-depth, proprietary research to more than 40 of the top US banks, support more than 2,100 financial services organizations with compliance and professional development training, provide trusted, relevant thought leadership through BAI Banking Strategies reports, podcasts and webinars, and offer specialized events and programs. For more information, visit www.bai.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005646/en/
Contact information
Holly Hughes
BAI, Chicago
hhughes@bai.org
+1 (312) 683-2305
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom